Santen Pharmaceutical Co., Ltd. (TYO:4536)

Market Cap	562.15B
Revenue (ttm)	300.00B
Net Income (ttm)	36.25B
Shares Out	334.51M
EPS (ttm)	103.68
PE Ratio	16.21
Forward PE	16.38
Dividend	38.00 (2.28%)
Ex-Dividend Date	Sep 29, 2025

Volume	382,300
Average Volume	1,126,630
Open	1,685.50
Previous Close	1,680.50
Day's Range	1,670.00 - 1,691.50
52-Week Range	1,310.50 - 1,878.50
Beta	0.22
RSI	57.79
Earnings Date	Aug 7, 2025

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4536

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.